In addition, since JAK-STAT pathway is important for various physiological functions, only HCC patients with upregulated JAK-STAT signaling could be treated with JAK inhibitors, thus a therapeutic window may exist. This evidence concerns the gene SOAT1 and hepatocellular carcinoma.